Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

There was no OS improvement for PD-L1 inhibitor Imfinzi (durvalumab) either alone or in combination with AZ’s experimental CTLA4 inhibitor tremelimumab in previously-untreated stage IV NSCLC patients with ... higher levels of PD-L1 expression in their

Latest news

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... And in the meantime, Opdivo/Yervoy’s lucrative position in

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    Mondher Mahjoubi. There are established ties between the two companies, as monalizumab is already being trialled in combination with AZ’s PD-L1 inhibitor Imfinzi (durvalumab), which stems from an initial ... 1/PD-L1 drugs.

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    which said the improvements were “consistent regardless of PD-L1 expression and across all risk groups.”. ... with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin (bevacizumab) to Sutent, which showed positive

  • China’s Innovent to start US trials of anti-CD47 cancer drug China’s Innovent to start US trials of anti-CD47 cancer drug

    trials after PD-1 inhibitor sintilimab (IBI-308) – partnered with Eli Lilly – got a green light earlier this year. ... Sintilimab is being positioned initially for the Chinese market, given the wealth of competition in the PD-1/PD-L1 inhibitor

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    PD-L1 inhibitor Imfinzi (durvalumab) reduced the risk of death by 32% compared to placebo after standard chemotherapy in the PACIFIC trial, consolidating earlier results which showed that the drug extended ... Imfinzi plus experimental CTLA4 inhibitor

More from news
Approximately 4 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics